Does State Medicaid Cover Enclomiphene Citrate?

What Is Enclomiphene Citrate and Why Does Medicaid Classification Matter?

Enclomiphene is the trans-isomer of clomiphene citrate. Clomiphene (Clomid) is FDA-approved for female infertility, but enclomiphene as a standalone agent was never granted FDA approval despite multiple NDA submissions for secondary hypogonadism in men. That regulatory gap matters enormously for Medicaid because federal Medicaid statute generally limits reimbursement to drugs with at least one FDA-approved indication listed in a CMS-recognized compendia, unless a state has obtained a specific waiver or written an explicit off-label policy.

The Medicaid Drug Rebate Program (MDRP) requires manufacturers to sign a rebate agreement before their drug is eligible for federal matching funds. Because enclomiphene has no approved NDA, it lacks a National Drug Code eligible for MDRP rebates, which means states pay 100% of the drug cost without federal financial participation for that specific agent. That economic reality is the single largest structural barrier to coverage, independent of any clinical debate about efficacy.

Testosterone deficiency affects an estimated 10 to 40% of men depending on the threshold used, according to data compiled by the Endocrine Society's 2018 clinical practice guideline on male hypogonadism. Secondary hypogonadism, where the testes are functional but upstream signaling is deficient, is the specific subtype where enclomiphene's mechanism as a selective estrogen receptor modulator (SERM) is clinically relevant. By blocking hypothalamic estrogen receptors, it increases GnRH pulsatility, which drives LH and FSH upward, stimulating endogenous testosterone production rather than replacing it exogenously.

The FDA Regulatory History That Drives Coverage Decisions

Repros Therapeutics submitted two NDAs for Androxal (enclomiphene citrate 12.5 mg and 25 mg) targeting secondary hypogonadism. The FDA issued a complete response letter in 2013 and again in 2016, citing concerns about the cardiovascular and thromboembolic safety dataset. Without an approval, enclomiphene cannot appear on any state Medicaid formulary as a covered, rebatable brand drug.

The 2016 Kim et al. randomized controlled trial published in BJU International (N=182) remains one of the most frequently cited efficacy references. That trial showed enclomiphene 12.5 mg and 25 mg both restored serum testosterone to normal range (greater than 300 ng/dL) in men with secondary hypogonadism more reliably than topical testosterone gel at 16 weeks, while preserving sperm parameters. Testosterone gel reduced sperm concentration by a median of 77% from baseline, whereas enclomiphene groups saw no significant sperm suppression. That fertility-preservation advantage is the primary clinical argument prescribers make in prior authorization letters, but it does not override the coverage exclusion for unapproved drugs in most states.

Compounded enclomiphene has filled the market gap. FDA's 503A compounding framework allows licensed pharmacies to prepare individualized prescriptions, but compounded drugs are not FDA-approved products and are therefore never eligible for Medicaid reimbursement under standard program rules. A patient receiving a compounded enclomiphene capsule must pay cash.

How State Medicaid Programs Classify Off-Label Drugs

Federal law under 42 U.S.C. 1396r-8(d)(1)(B) permits states to exclude or require prior authorization for any drug. States that do cover off-label uses typically rely on one of three recognized compendia: the American Hospital Formulary Service Drug Information (AHFS-DI), the Micromedex DrugDex database, or clinical literature cited in peer-reviewed sources. Because enclomiphene is not listed as an approved drug in AHFS-DI or DrugDex with a supported off-label rating for secondary hypogonadism, states have almost no compendial basis to justify coverage.

A 2022 analysis of state Medicaid preferred drug lists found that fewer than half of state programs covered GLP-1 receptor agonists for obesity, even after FDA approval, according to KFF's Medicaid Drug Coverage tracker. If approved drugs face that barrier, unapproved ones face a steeper climb. The practical result is that, as of mid-2025, no state Medicaid program is known to have a standing written policy explicitly covering enclomiphene citrate as a covered outpatient benefit.

Prior Authorization Criteria: What States That Review Requests Typically Require

In states where a physician submits a prior authorization request for enclomiphene despite the general exclusion, the clinical documentation reviewers look for maps closely to the Endocrine Society's diagnostic criteria for male hypogonadism: at least two morning serum total testosterone measurements below 300 ng/dL, plus symptoms consistent with androgen deficiency (reduced libido, fatigue, loss of lean mass, depressive mood), and a documented evaluation of the pituitary-testicular axis confirming a secondary (central) etiology with normal or low LH/FSH.

Beyond baseline labs, reviewers typically require:

• Documentation that the prescriber considered first-line guideline-recommended therapy (exogenous testosterone, either intramuscular or transdermal)
• A clinical rationale for why the patient cannot use approved testosterone formulations (allergy, skin sensitivity, transfer risk to partners or children, desire to preserve fertility)
• Baseline semen analysis if fertility preservation is cited as the indication
• A proposed monitoring plan including serum testosterone, LH, FSH, hematocrit, and estradiol at 8 to 12 weeks

The Endocrine Society guideline explicitly states: "We suggest treatment with testosterone therapy in men who have symptomatic androgen deficiency and unequivocal biochemical evidence of testosterone deficiency." That language defaults to exogenous testosterone, which means any PA letter advocating for enclomiphene must affirmatively explain why the guideline's preferred approach is clinically unsuitable for the individual patient.

Step Therapy Requirements for Enclomiphene on Medicaid

Step therapy, sometimes called "fail-first" policy, requires a patient to try and fail at least one preferred or lower-cost therapy before an alternative is approved. For male hypogonadism, Medicaid programs that review enclomiphene requests typically require documented failure of or contraindication to at least one FDA-approved testosterone product.

FDA-approved testosterone formulations include testosterone cypionate injection (generic available since the 1950s), testosterone enanthate injection, transdermal gels (AndroGel, Testim, Vogelxo), a buccal system (Striant), a nasal gel (Natesto), and subcutaneous pellets (Testopel). Generic testosterone cypionate 200 mg/mL typically costs less than $30 per 10 mL vial at retail, making it the anchor comparator for any cost-effectiveness argument.

A prescriber documenting step therapy failure should include specific dates, doses, duration, serum testosterone response, and the precise adverse effect or clinical outcome that made continued use inappropriate. Vague statements such as "patient did not tolerate testosterone" rarely satisfy PA reviewers. A chart note documenting a hematocrit above 52% on testosterone cypionate, a confirmed allergy, or documented semen analysis showing azoospermia induced by exogenous testosterone carries far more weight.

The 2021 AUA/ASRM guideline on male infertility specifically recommends against exogenous testosterone in men who wish to preserve fertility, stating that testosterone therapy suppresses the hypothalamic-pituitary-gonadal axis and impairs spermatogenesis. Citing this guideline directly in a PA request can justify skipping the testosterone step-therapy requirement when fertility preservation is the documented clinical goal.

Formulary Tier and Drug Cost Implications

Because enclomiphene has no NDA, it is not assigned a formulary tier in any standard state Medicaid preferred drug list. Compounded versions carry no NDC code eligible for pharmacy adjudication. The practical consequence is that even a sympathetic Medicaid managed care plan cannot process a claim for compounded enclomiphene through its standard pharmacy benefit; the claim will reject at the switch before it reaches a human reviewer.

The only pathway to coverage would be via a medical exception approved through the plan's medical policy department, which requires physician-to-physician peer review and written medical necessity documentation. CMS's guidance on Medicaid managed care access requirements mandates that managed care organizations maintain an exceptions and appeals process that is no more restrictive than fee-for-service Medicaid.

For reference, a 2023 GoodRx analysis placed compounded enclomiphene at roughly $60 to $150 per month at 503A pharmacies, depending on dose and supplier. That is substantially below the cost of branded testosterone gels (AndroGel 1.62% retails above $500/month without insurance) but still a meaningful out-of-pocket expense for Medicaid-eligible patients, who by definition have limited income.

How to Appeal a Medicaid Denial of Enclomiphene

Every Medicaid enrollee in the United States has a federally guaranteed right to a fair hearing when coverage is denied, reduced, or terminated. 42 CFR Part 431, Subpart E sets the federal floor: states must provide written notice of the denial with the specific reason, and the enrollee must be given at least 90 days to request a hearing. Managed care enrollees get an internal appeal first, then an external independent review, then the state fair hearing.

A successful appeal for enclomiphene denial typically moves through four stages:

Stage 1: Internal plan grievance (MCO enrollees only). Submit within 60 days of the denial. Include the treating physician's letter with the complete clinical rationale, copies of all lab results, and citations to peer-reviewed literature. The 2016 Kim et al. BJU International study and the AUA/ASRM guideline language on fertility preservation are the two most cited documents in successful appeals.

Stage 2: External independent medical review. If the internal appeal fails, request an independent medical review (IMR) through the state's designated external review organization. The ACA requires states to offer external review for managed care denials under 42 CFR 438.400. The IMR reviewer is a board-certified specialist, usually a urologist or endocrinologist, who reviews the case blind to cost.

Stage 3: State Medicaid fair hearing. Administered by the state's office of administrative hearings. The hearing is quasi-judicial; both the patient (or their representative) and the Medicaid agency present evidence. The administrative law judge can overturn the denial if the agency's decision was not supported by substantial evidence or violated the plan's own coverage rules.

Stage 4: State or federal court. Rarely reached. Applicable when the fair hearing decision itself violated federal Medicaid law or a constitutional provision.

A 2019 JAMA Internal Medicine analysis of Medicaid prior authorization denials found that physicians who submitted complete clinical documentation with peer-reviewed citations had a significantly higher overturn rate at the appeal stage than those who submitted only a form letter. Specificity of clinical documentation, not volume, determined outcomes.

What Physicians Should Include in the Medical Necessity Letter

The letter should open with the patient's diagnosis code (ICD-10 E29.1 for testicular hypofunction, or E23.0 for hypopituitarism if a central cause is confirmed), followed by two dated testosterone values, symptomatic history, and LH/FSH levels confirming a secondary pattern. Each prior therapy tried should appear with dates, doses, duration, and the specific reason it was discontinued or is contraindicated.

The letter should cite: (1) Kim et al. 2016 in BJU International for enclomiphene's efficacy and sperm-preservation data; (2) the Endocrine Society 2018 guideline for diagnostic threshold and treatment rationale; (3) the AUA guideline on male infertility for the contraindication of exogenous testosterone in men seeking fertility. A monitoring plan with follow-up labs at 8 and 16 weeks demonstrates that the prescriber intends to document clinical response, which addresses the payer's outcome-tracking concern.

The American Society for Reproductive Medicine's (ASRM) practice committee opinion on male infertility evaluation also supports SERM use in men with secondary hypogonadism as an alternative to testosterone therapy when fertility is a goal. Including the ASRM citation alongside the AUA guideline gives the appeal letter dual-society backing.

Enclomiphene for Weight Loss: Does Medicaid Cover That?

No. Enclomiphene has no clinical trial evidence supporting use for obesity or weight loss, no FDA approval for that indication, and no compendial support in AHFS-DI or DrugDex. Medicaid programs that restrict GLP-1 receptor agonists for obesity, drugs with actual FDA approval under SURMOUNT and STEP trial data, would have zero basis to cover enclomiphene for that purpose.

STEP-1 (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. Even with that level of evidence, fewer than half of state Medicaid programs cover semaglutide for obesity as of 2024 per KFF tracking data. Enclomiphene's weight-loss evidence does not approach that threshold.

The biochemical rationale sometimes proposed is that restoring testosterone to normal range in hypogonadal men may improve body composition. A meta-analysis by Corona et al. (2016, published in Endocrine Reviews) found that testosterone replacement in hypogonadal men reduced fat mass by a mean of 1.6 kg and increased lean mass by 1.7 kg. That modest effect on body composition does not constitute a weight-loss indication, and no Medicaid program would accept it as such.

Can Manufacturer Savings Cards Be Used With Medicaid?

No. Federal anti-kickback statute (42 U.S.C. 1320a-7b) explicitly prohibits using manufacturer coupons, savings cards, or copay assistance programs in conjunction with any federal health care program, including Medicaid. The Office of Inspector General has issued multiple advisory opinions and special fraud alerts on this point. A patient using a manufacturer coupon to reduce out-of-pocket cost on a Medicaid claim could expose both themselves and the pharmacy to federal liability.

Because compounded enclomiphene is a cash-pay drug with no Medicaid claim adjudication, a patient paying entirely out of pocket for a compound (not using Medicaid to pay any portion) is not subject to this restriction. The restriction applies only when a federal program is paying any part of the drug cost.

State-by-State Variability: What to Check Before Submitting a Claim

No two state Medicaid programs have identical off-label drug policies. Before a practice submits any prior authorization for enclomiphene, the prescriber's billing team should confirm three things with the specific state program:

First, confirm whether the state has a written off-label drug coverage policy at all. States like California (Medi-Cal) and New York (NY Medicaid) have published off-label review processes; many smaller states do not. CMS's Medicaid Drug Policy page provides links to state preferred drug list resources.

Second, confirm whether the specific patient is enrolled in fee-for-service Medicaid or a Medicaid managed care organization (MCO). MCOs often have their own formularies and PA criteria that differ from the state's fee-for-service policy. As of 2023 to 72% of all Medicaid beneficiaries were enrolled in comprehensive managed care, according to CMS enrollment data.

Third, check the state's current preferred drug list (PDL) for the testosterone/androgen category to understand what step therapy is expected. The National Medicaid SPDL resource compiles state drug utilization data that can help identify which testosterone products a state has placed on preferred status, and therefore what "fail-first" requirement a patient must document.

Monitoring Parameters During Enclomiphene Therapy

If a patient does access enclomiphene through a successful appeal or cash-pay route, clinically appropriate monitoring follows the same framework used in the Kim et al. trial and outlined by the Endocrine Society. Serum total testosterone should be measured at 8 weeks after initiation. The Endocrine Society guideline recommends a target total testosterone in the mid-normal range, approximately 400 to 700 ng/dL, to minimize erythrocytosis risk while achieving symptom relief.

LH, FSH, and estradiol should be checked at the same visit. Because enclomiphene blocks estrogen receptors, estradiol can paradoxically rise in some patients as aromatization of the increased testosterone occurs; a level above 60 pg/mL may require dose adjustment. Hematocrit should be checked at baseline and at 16 weeks; although enclomiphene carries less erythrocytosis risk than exogenous testosterone, polycythemia can still develop. FDA guidance on testosterone product labeling specifically calls out hematocrit monitoring as a class requirement.

For men where fertility preservation drove the prescription, a follow-up semen analysis at 12 to 16 weeks provides objective data that can also serve as documentation for any ongoing coverage appeal, demonstrating that the drug is meeting the clinical goal that justified it.